- Home
- WNW vs PMCB Comparison
WNW vs PMCB Comparison
Compare WNW & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNW
- PMCB
- Stock Information
- Founded
- WNW 2015
- PMCB 1996
- Country
- WNW China
- PMCB United States
- Employees
- WNW N/A
- PMCB N/A
- Industry
- WNW Catalog/Specialty Distribution
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WNW Consumer Discretionary
- PMCB Health Care
- Exchange
- WNW Nasdaq
- PMCB Nasdaq
- Market Cap
- WNW 6.9M
- PMCB 7.1M
- IPO Year
- WNW 2020
- PMCB N/A
- Fundamental
- Price
- WNW $1.71
- PMCB $1.02
- Analyst Decision
- WNW
- PMCB
- Analyst Count
- WNW 0
- PMCB 0
- Target Price
- WNW N/A
- PMCB N/A
- AVG Volume (30 Days)
- WNW 26.2K
- PMCB 9.7K
- Earning Date
- WNW 07-07-2025
- PMCB 03-17-2025
- Dividend Yield
- WNW N/A
- PMCB N/A
- EPS Growth
- WNW N/A
- PMCB N/A
- EPS
- WNW 9.06
- PMCB 1.29
- Revenue
- WNW $158,485.00
- PMCB N/A
- Revenue This Year
- WNW N/A
- PMCB N/A
- Revenue Next Year
- WNW N/A
- PMCB N/A
- P/E Ratio
- WNW $0.19
- PMCB $0.86
- Revenue Growth
- WNW N/A
- PMCB N/A
- 52 Week Low
- WNW $0.95
- PMCB $1.00
- 52 Week High
- WNW $70.00
- PMCB $2.42
- Technical
- Relative Strength Index (RSI)
- WNW 44.39
- PMCB 41.38
- Support Level
- WNW $1.62
- PMCB $1.05
- Resistance Level
- WNW $1.80
- PMCB $1.14
- Average True Range (ATR)
- WNW 0.12
- PMCB 0.07
- MACD
- WNW 0.02
- PMCB 0.01
- Stochastic Oscillator
- WNW 32.62
- PMCB 13.33
About WNW Meiwu Technology Company Limited
Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments: Clean Food Platform; Restaurant; and Others. The company generates the majority of its revenue from Technical services.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.